ATE157873T1 - Verwendung von benzodiazepinverbindungen zur herstellung eines arzneimittels gegen mit excitatorischen aminosäuren verbundene zentralnervensystem-störungen - Google Patents

Verwendung von benzodiazepinverbindungen zur herstellung eines arzneimittels gegen mit excitatorischen aminosäuren verbundene zentralnervensystem-störungen

Info

Publication number
ATE157873T1
ATE157873T1 AT91104888T AT91104888T ATE157873T1 AT E157873 T1 ATE157873 T1 AT E157873T1 AT 91104888 T AT91104888 T AT 91104888T AT 91104888 T AT91104888 T AT 91104888T AT E157873 T1 ATE157873 T1 AT E157873T1
Authority
AT
Austria
Prior art keywords
amino acids
nervous system
central nervous
excitatory amino
production
Prior art date
Application number
AT91104888T
Other languages
English (en)
Inventor
Leif Helth Jensen
Jorgen Drejer
Frank Waetjen
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of ATE157873T1 publication Critical patent/ATE157873T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT91104888T 1990-04-13 1991-03-27 Verwendung von benzodiazepinverbindungen zur herstellung eines arzneimittels gegen mit excitatorischen aminosäuren verbundene zentralnervensystem-störungen ATE157873T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50928490A 1990-04-13 1990-04-13

Publications (1)

Publication Number Publication Date
ATE157873T1 true ATE157873T1 (de) 1997-09-15

Family

ID=24026006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91104888T ATE157873T1 (de) 1990-04-13 1991-03-27 Verwendung von benzodiazepinverbindungen zur herstellung eines arzneimittels gegen mit excitatorischen aminosäuren verbundene zentralnervensystem-störungen

Country Status (12)

Country Link
EP (1) EP0451626B1 (de)
JP (1) JP3015129B2 (de)
AT (1) ATE157873T1 (de)
CA (1) CA2040242A1 (de)
DE (1) DE69127572T2 (de)
DK (1) DK0451626T3 (de)
ES (1) ES2108017T3 (de)
FI (1) FI911784A (de)
GR (1) GR3025186T3 (de)
IE (1) IE910939A1 (de)
NO (1) NO911449L (de)
PT (1) PT97365B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5317018A (en) * 1992-06-09 1994-05-31 Armin Walser Benzodiazepines and compositions for treating anxiety and panic disorders, and idiopathic and psychomotor epilepsy
CA2450801C (en) * 1992-07-24 2009-11-17 The Regent Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
US5852008A (en) * 1995-01-24 1998-12-22 The Regents Of The University Of California Heteroatom substituted benzoyl derivatives that enhance synaptic response mediated by receptors
GB2346883B (en) * 1996-09-02 2001-02-14 Lilly Industries Ltd GluR5 receptor binding assay
KR102362725B1 (ko) * 2018-10-22 2022-02-15 (주)엘엑스하우시스 창호 시공용 낙하방지망 조립체

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC1528A1 (fr) * 1982-07-21 1984-04-13 Hoffmann La Roche Imidazobenzodiazepines
CA1327008C (en) * 1988-01-15 1994-02-15 Walter Merz Anti-psychotic imidazobenzodiazepine

Also Published As

Publication number Publication date
PT97365B (pt) 1998-08-31
CA2040242A1 (en) 1991-10-14
ES2108017T3 (es) 1997-12-16
FI911784A0 (fi) 1991-04-12
EP0451626B1 (de) 1997-09-10
DE69127572D1 (de) 1997-10-16
GR3025186T3 (en) 1998-02-27
JP3015129B2 (ja) 2000-03-06
EP0451626A3 (en) 1992-10-07
NO911449D0 (no) 1991-04-12
PT97365A (pt) 1992-01-31
DK0451626T3 (da) 1998-04-20
IE910939A1 (en) 1991-10-23
EP0451626A2 (de) 1991-10-16
JPH04224516A (ja) 1992-08-13
NO911449L (no) 1991-10-14
FI911784A (fi) 1991-10-14
DE69127572T2 (de) 1998-01-22

Similar Documents

Publication Publication Date Title
DE69201948D1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
FI941378A0 (fi) Bentsimidatsoliyhdisteitä, niiden käyttö ja valmistus
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
HU9600834D0 (en) Quinazoline derivatives
DE69317898D1 (de) 3,3-diphenylpropylamine, ihre verwendung und herstellung
ATE206919T1 (de) Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen
DE3888340D1 (de) Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
DE68908145D1 (de) Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien.
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
FI935800A (fi) Masennuksenvastaisia ja Parkinsonin taudin vastaisia yhdisteitä
ATE157873T1 (de) Verwendung von benzodiazepinverbindungen zur herstellung eines arzneimittels gegen mit excitatorischen aminosäuren verbundene zentralnervensystem-störungen
DE3586649D1 (de) Verwendung von spergualinderivaten zur herstellung von arzneimitteln mit immunodepressiver wirkung.
DE69021347D1 (de) Isatinderivate, ihre Herstellung und Verwendung.
ATE186215T1 (de) Verwendung von n-(pyridinyl)-1h-indol-1-aminen zur herstellung eines medikamentes zur behandlung von zwangsneurotischen erkrankungen
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE236634T1 (de) Verwendung von 4-piperidinmethanolderivaten zur behandlung von neuralentwicklungsstörungen
ATE136217T1 (de) Verwendung von imino-derivaten von etianaldehyd zur herstellung eines arzneimittels zur behandlung des bluthochdrucks
DE69619088D1 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
IT1241927B (it) 3'-deamino-4'-deossi-4'-amino-8-fluoroantra- cicline processi per la loro preparazione e composizioni farmaceutiche che le contengono
DE69327077T2 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
ITMI920082A1 (it) Derivati solforati di acidi biliari

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee